Erratum: Vol. 67, No. 43

Weekly / March 8, 2019 / 68(9);233

Print
Related Pages
View suggested citation
Table
Related Materials

In the report “Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel,” errors occurred in Table 1. The corrected Table 1 is below.

Top

TABLE 1. Recommendations for postexposure prophylaxis and preexposure protection, by age group and risk categoryReturn to your place in the text
Indication/Age group Risk category/Health status Hepatitis A vaccine Immune globulin*
Postexposure prophylaxis
<12 mos Healthy No 0.1 mL/kg
12 mos–40 yrs Healthy 1 dose† None
>40 yrs Healthy 1 dose† 0.1 mL/kg§
≥12 mos Immunocompromised or chronic liver disease 1 dose† 0.1 mL/kg
≥12 mos Vaccine contraindicated** No 0.1 mL/kg
Preexposure protection††
<6 mos Healthy No 0.1–0.2 mL/kg§§
6–11 mos Healthy 1 dose¶¶ None
12 mos–40 yrs Healthy 1 dose*** None
>40 yrs Healthy 1 dose*** 0.1–0.2 mL/kg§§,†††
>6 mos Immunocompromised or chronic liver disease 1 dose*** 0.1–0.2 mL/kg§§,†††
>6 mos Persons who elect not to receive vaccine or for whom vaccine is contraindicated No 0.1–0.2 mL/kg§§

* Measles, mumps, and rubella vaccine should not be administered for at least 3 months after receipt of immune globulin.
† A second dose is not required for postexposure prophylaxis; however, for long-term immunity, the hepatitis A vaccination series should be completed with a second dose at least 6 months after the first dose.
§ The provider’s risk assessment should determine the need for immune globulin administration. If the provider’s risk assessment determines that both vaccine and immune globulin are warranted, Hepatitis A vaccine and immune globulin should be administered simultaneously at different anatomic sites.
Vaccine and immune globulin should be administered simultaneously at different anatomic sites.
** Life-threatening allergic reaction to a previous dose of hepatitis A vaccine, or allergy to any vaccine component.
†† Immune globulin should be considered before travel for persons with special risk factors for either hepatitis A virus (HAV) infection or increased risk for complications in the event of exposure to HAV.
§§ 0.1 mL/kg for travel up to 1 month; 0.2 mL/kg for travel up to 2 months, 0.2 mL/kg every 2 months for travel of ≥2 months’ duration.
¶¶ This dose should not be counted toward the routine 2-dose series, which should be initiated at age 12 months.
*** For persons not previously vaccinated with HepA vaccine, administer dose as soon as travel is considered, and complete series according to routine schedule.
††† May be administered, based on providers’ risk assessment.

Top


Suggested citation for this article: Erratum: Vol. 67, No. 43. MMWR Morb Mortal Wkly Rep 2019;68:233. DOI: http://dx.doi.org/10.15585/mmwr.mm6809a4.

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

View Page In: PDF [51K]